•  
  •  
 

Article Type

Original Study

Abstract

Objective The aim of this study was to examine the role of the endogenous secretory receptor for advanced glycation end products (esRAGE) as a biochemical marker for hypertensive patients with type II diabetes mellitus. Background Advanced glycation end products may cause vascular stiffening by forming cross-links through the collagen molecule or by interaction with their cellular transductional receptor [receptor for advanced glycation end products (RAGE)]. A secreted isoform of RAGE, termed endogenous secretory receptor for advanced glycation end products, may contribute toward the removal/detoxification of advanced glycation end products by acting as a decoy. This work aimed to study the role of esRAGE in hypertensive and diabetic patients. Participants and methods This study included 60 patients (20 patients with type II diabetes mellitus, 20 hypertensive patients, and 20 hypertensive type II diabetic patients) and 20 healthy individuals as a control group. The patients were recruited from the Cardiology Department, Menofia University Hospital. The studied participants were subjected to a full assessment of history, clinical examination (including measurement of blood pressure), and laboratory investigations including measurement of fasting blood glucose, lipid profile, urea, and creatinine measured using the enzymatic colorimetric method and esRAGE determined by the enzyme-linked immunosorbent assay measured by the ELISA technique. Results The results of the present study showed that the levels of serum esRAGE were significantly lower in all patient groups compared with the control group (P<0.001). esRAGE levels were also significantly lower in type II diabetic hypertensive patients than in hypertensive or diabetic patients alone (P<0.001). In the patient group, there was a significantly negative correlation between esRAGE and each of systolic and diastolic blood pressure, triacylglycerol, total cholesterol, and low-density lipoprotein cholesterol, whereas a significant positive correlation was found with high-density lipoprotein cholesterol. Conclusion esRAGE may be a novel and potential protective factor for essential hypertension and type II diabetic patients.

Download

Share

COinS